A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) - CA209-7G8
Updated: 26 June, 2020 | ClinicalTrials.gov
Print Friendly Summary
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion: - Predominant histologic component (> 50%) must be urothelial (transitional cell) carcinoma - Persistent or recurrent disease ≤ 24 months of last BCG dose, but not classified as BCG unresponsive - Histologically confirmed persistent or recurrent high-risk non-muscle-invasive urothelial carcinoma (UC) - Treated with at least 1 adequate course of induction BCG therapy (at least 5 out of 6 doses) - Sufficient tissue for both biomarker analysis and central pathology review committee (PRC) confirmation of diagnosis - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 - Women of child bearing potential (WOCBP) and men with WOCBP partners must agree to follow contraceptive requirements Exclusion Criteria - Previous or concurrent muscle invasive, locally advanced, or disseminated/metastatic UC - UC in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment - UC and/or CIS in the prostatic urethra within 12 months of enrollment - Prior surgery (other than transurethral resection of the bladder tumor (TURBT)/biopsies) for bladder cancer; prior radiation therapy, or systemic chemotherapy or immunotherapy for bladder cancer or UC Other inclusion/exclusion criteria apply.